AbbVie, Gilead Sciences, Cardinal Health, Merck, Bristol Myers, and Amgen are large-cap healthcare companies that have the capacity to grow…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
The stock has been beating the market this year -- and that says a lot....…
The biopharma company has a lot riding on its new drugs....…
Health Care Up After Bristol Myers Earnings -- Health Care Roundup...…
BMY earnings call for the period ending September 30, 2022....…
Bristol-Myers (BMY) third-quarter 2022 earnings beat estimates while sales miss the same due to a decline in sales of Revlimid....…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Bristol Myers Squibb CEO Dr. Giovanni Caforio joins CNBC's 'Squawk on the Street' to discuss the company's third-quarter earnings report....…
Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…
Shares of Bristol Myers Squibb were up 1.2% in premarket trading on Wednesday, the day after the company shared…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Sales of the company's blockbuster cancer drug Revlimid, which has faced increased competition this year, tumbled 28% in the quarter....…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Bristol Myers (BMY) delivered earnings and revenue surprises of 8.74% and 1.63%, respectively, for the quarter ended September 2022. Do…
...Oct 25 (Reuters) - Drugmaker Bristol Myers Squibb
said on Tuesday its......…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Jenny Hsieh joins Actinium as Chief Strategy Officer from Gilead Sciences, following its acquisition of Immunomedics Sunitha Lakshminarayanan, Senior Vice…
Here is a look at what to expect when these three companies report quarterly results before markets open on Wednesday....…
Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs…
NEW YORK, Oct. 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, BMY, NOC, BNTX, and TSLA. Click…
Bristol Myers: FDA to Review Camzyos to Reduce Septal-Reduction Therapy Need...…
Bristol Myers Squibb (BMY) closed at $70.62 in the latest trading session, marking a -0.21% move from the prior day....…
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients…
Within the last quarter, Bristol-Myers Squibb (NYSE:BMY) has observed the following analyst ratings:
Latest Ratings for BMY
…
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring…
Within the last quarter, Bristol-Myers Squibb (NYSE:BMY) has observed the following analyst ratings:
Latest Ratings for BMY
…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Bristol Myers Squibb (BMY) closed at $70.24 in the latest trading session, marking a -1.69% move from the prior day....…
Also, new options-trade recommendations for Harmonic and Bristol-Myers Squibb....…
Das Instrument BRM US1101221083 BRISTOL-MYERS SQUIBBDL-10 EQUITY wird ex Dividende/Zinsen gehandelt am 06.10.2022
The instrument BRM US1101221083 BRISTOL-MYERS SQUIBBDL-10 EQUITY has…
Underrepresented biotech founders developing novel health solutions will gain access to LabCentrals lab space, resources and community CAMBRIDGE, Mass., Oct.…
NEW YORK CITY (dpa-AFX) - Exelixis, Inc. (EXEL) announced the expansion of clinical trial collaboration and supply agreement with Bristol-Myers…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Autolus Therapeutics Shares Jump After Cancer-Collaboration Agreement with Bristol Myers...…
BMYs YTD performance indicates the stock has been a viable hedge against inflation because people can ill afford to cut…
Bristol Myers (BMY) expects recent drug approvals to generate an incremental stream of revenues and combat competition for its key…
New York (Reuters) - Der US-Pharmakonzern Bristol Myers Squibb hat im ersten Quartal besser als erwartet abgeschnitten und seine Ergebnisprognose…